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Multiple myeloma (MM) is characterized as a clonal ex-
pansion of malignant plasma cells in the bone marrow, 
which is often associated with pancytopenia and os-
teolytic bone disease. Interestingly, myeloma-infiltrated 
bone marrow is considered to be hypoxic, providing se-
lection pressure for a developing tumour. Since HSP90 
was shown to participate in stabilization of the subunit 
of the key transcription factor HIF-1, which controls the 
hypoxic response, the aim of this study was to investi-
gate the influence of a HSP90 inhibitor 17-allylamino-
17-demethoxygeldanamycin (17-AAG), on MM cells cul-
tured under low oxygenation conditions. We confirmed 
that 17-AAG inhibits hypoxic induction of the HIF-1 tar-
get genes in malignant plasma cells and demonstrate 
the concentration range of severe hypoxia-specific cy-
totoxicity. Next, we selected the malignant plasma cells 
under severe hypoxia/re-oxygenation culture conditions 
in the presence or absence of 17-AAG and subsequently, 
the cells which survived were further expanded and ana-
lyzed. Interestingly, we have noticed significant changes 
in the survival and the response to anti-MM drugs be-
tween the parental cell lines and those selected in cyclic 
severe hypoxia in the presence and absence of 17-AAG. 
Importantly, we also observed that the lack of oxygen it-
self, irrespectively of HIF-1 inhibition, is the main/pivotal 
factor driving the selection process in the experiments 
presented here.
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INTRODUCTION
Multiple Myeloma (MM) is an incurable B-cell malig-
nancy, described as malignant expansion of monoclonal 
plasma cells in the bone marrow (BM). Transforma-
tion of a normal plasma cell into aggressive myeloma 
is a multistep process which requires the accumulation 
of multiple genetic “hits”. During disease progression, 
myeloma cells are closely dependent on the BM en-
vironment, indicating that interaction with the niche 
plays a crucial role in the development of this tumor 
(Palumbo & Anderson, 2011). According to the cur-
rent status of knowledge, MM shows a heterogeneous 
subclonal structure at diagnosis (Bianchi & Ghobrial, 
2014), which evolves further in parallel to differential 
response of subclones to micro-environmental pressure 
(Bolli et al., 2014).
In the cancerogenesis, one of the most important 
micro-environmental selection factors is hypoxia (Grae-
ber et al., 1996). Although the presence of low oxygen 
pressure in normal (Levesque et al., 2007; Parmar et al., 
2007; Levesque and Winkler, 2011) and MM-infiltrated 
mouse BM (Asosingh et al., 2005) was reported in sev-
eral studies, the importance of hypoxia in the progres-
sion of MM has not yet been fully elucidated. Studies by 
Colla et al., Giatromanolaki et al., Martin et al. and Borsi 
et al. (Colla et al., 2010; Giatromanolaki et al., 2010; Mar-
tin et al., 2010; Borsi et al., 2014), on malignant plasma 
cells confirmed nuclear accumulation of HIF-1 (Hypoxia 
Inducible Factor-1), the key transcription factor for hy-
poxia response (stabilized in hypoxic conditions < 2% 
O2), which upregulates several genes to promote survival 
under low-oxygen conditions (Semenza, 2003). Interest-
ingly, however, direct measurement of oxygen pressure 
in human BM, performed by Colla et al. did not prove 
occurrence of hypoxia. Thus, nuclear accumulation of 
HIF-1 observed in malignant plasma cells, in parallel to 
relatively high oxygen partial pressure reported in hu-
man MM-infiltrated BM by Colla and coworkers (above 
50 mmHg, 6.5% O2), could be most probably explained 
as heterogeneity in the local oxygen distribution in the 
bone marrow, supporting the hypothesis of hypoxia 
niches (Hu et al., 2012). Alternatively, in malignant plas-
ma cells, the nuclear HIF-1 accumulation could be hy-
poxia-independent, as reported by the Anderson labora-
tory, which demonstrated HIF-1 protein stabilization and 
activity in some MM patients under normoxic conditions 
(Zhang et al., 2009).
Several findings in solid tumors support the hypoth-
esis that exposure to hypoxia and re-oxygenation pro-
vides a strong selection pressure contributing to the en-
richment of cancer stem cells (Keith & Simon, 2007; Li 
& Rich, 2010). In MM, hypoxia was reported to induce 
immature phenotype of malignant cells and the acquisi-
tion of a quiescent state (Muz et al., 2014). Moreover, 
enhanced tumor initiation and increased drug resistance 
to bortezomib and carfilzomib was observed in the hy-
poxic myeloma cells (Muz et al., 2014). In addition, study 
by Azab et al. revealed that hypoxia activates EMT (Ep-
ithelial Mesenchymal Transition) – related proteins and 
induces metastasis of malignant plasma cells by stimu-
lating the migration and homing to the new BM niches 
(Azab et al., 2012). Thus, the data published so far sug-
gest that targeting the hypoxic myeloma cells may serve 
as a promising therapeutic approach.
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According to current knowledge, besides the classical 
oxygen-dependent regulators of HIF-1 activity, the chap-
erone heat shock protein 90 (HSP90) was shown to sta-
bilize HIF-1 alpha subunit in oxygen-independent man-
ner, protecting it from proteasomal degradation (Isaacs 
et al., 2002; Koh and Powis, 2012). Thus, according to 
Scheme 1, application of 17-allylamino-17-demethoxy-
geldanamycin (17-AAG) – a potent inhibitor of HSP90 
chaperoning activity – may influence the MM cells’ re-
sponse to hypoxic conditions, especially in the light of 
the work by Mitsiades and coworkers (Mitsiades et al., 
2006), who demonstrated suppression of basal, normoxic 
HIF-1 alpha transcriptional activity in MM cells treated 
with 17-AAG under normoxic conditions. Considering 
pros and cons of interference in hypoxic signalling, one 
may speculate whether such disturbance/reprogramming 
of the cell’s response to hypoxic condition, resulting 
from impairment of HIF-1 alpha stabilization by HSP90, 
may serve as an additional driving force in the context 
of cell stemness and/or selection of more resistant MM 
clones/subclones.
In this paper we reported the influence of 17-AAG 
on MM cells cultured under low oxygenation conditions, 
revealing the increased compound toxicity against malig-
nant plasma cells cultured under chronic and cyclic se-
vere hypoxia (< 0.01% O2) in comparison to normoxic 
MM cells. In line with this data, we show for the first 
time that 17-AAG can block induction of the HIF-1 tar-
get genes in malignant plasma cells cultured in the hy-
poxic environment. Moreover, we performed the func-
tional comparison of cells selected in the presence and 
absence of 17-AAG demonstrating changes acquired 
during the selection process under cyclic severe hypoxia.
MATERIALS AND METHODS
Materials. 17-AAG was supplied by Sigma-Aldrich, 
reconstituted in sterile DMSO (Sigma Aldrich) and used 
at the micromolar concentration range. Doxorubicin was 
purchased from Sigma-Aldrich, reconstituted in sterile 
water (Cytogen) and used at the nanomolar concentra-
tion range. Bortezomib (Santa Cruz Biotechnology, Inc.) 
was supplied as a lyophilized powder, reconstituted in 
sterile DMSO (Sigma Aldrich) and used at the nanomo-
lar concentration range. 1 kb DNA ladder for agarose 
gel electrophoresis was supplied by Cytogen (Solis Bio-
dyne). Protein ladder was supplied by Thermo Fisher 
Scientific.
Cell culture. L363 and RPMI 8226 (obtained from 
German Collection of Microorganisms and Cell Cultures, 
DSMZ) were cultured in the RPMI1640 medium (Gib-
co, Life Technologies) containing 10% Heat Inactivated 
Fetal Bovine Serum (FBS) (Gibco, Life Technologies), 
100 units/ml penicillin (Sigma Aldrich), and 100 µg/ml 
streptomycin (Sigma Aldrich). Cells were cultured either 
under normal conditions (37°C and 5% CO2 equilibrated 
with atmospheric O2 that contained 21% O2) (hereafter 
referred to as normoxia) or in the Modular Incubator 
Chamber (Billups-Rothenberg, Inc., 5% CO2, 95% N2) 
that was placed at 37°C (hereafter referred to as severe 
hypoxia). To obtain the severe hypoxic conditions, the 
gas mixture of 5% CO2 and 95% N2 was flushed through 
the Modular Incubator Chamber at the flow rate of 25 
liters per minute for 10 minutes. Next, the chamber was 
returned to conventional incubator for 1 hour to allow 
culture media to de-gas and then the flush at the flow 
rate of 25 liters per minute was repeated for another 
10 minutes. According to the literature (Wu et al., 2011) 
and the manufacturer instructions (Billups-Rothenberg), 
10 minute flushing at the indicated flow rate completely 
purges the Modular Incubator Chamber, removing most 
if not all oxygen present in the chamber and in the cul-
ture media. Thus, the conditions obtained in the Modu-
lar Incubator Chamber were referred in accordance to 
literature (Papandreou et al., 2005; Achison et al., 2003) 
as severe hypoxia (< 0.01% O2).
RT-PCR. Total RNA was isolated using GenElute™ 
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. The quantity 
of total RNA was measured using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE). cDNA synthesis was performed using oligo 
(dT) 15 primer and GoScript Transcriptase according to 
the manufacturer’s instructions (Promega GmbH, Ger-
many). The PCR mixture contained: 1.5 µl of cDNA, 0.2 
µl of each 10 µM primers, 10 µl of Color OptiTaq PCR 
Master Mix (2x) (EURx, Poland) and 10 µl of nuclease 
free deionized water. Primers used were: SLC2A1 (Sol-
ute carrier family 2, facilitated glucose transporter mem-
ber 1) forward (5-TTGGCTCCGGTATCGTCAAC-3), 
SL2CA1 reverse (5-GGTCCGGCCTTTAGTCTCAG-3), 
PFKFB4 (6-Phosphofructo-2-Kinase/Fructose-2,6-Bi-
phosphatase 4) forward (5-GGGATGGCGTCCCCAC-
GGG-3), PFKFB4 reverse (5-CGCTCTCCGTTCTCG-
GGTG-3), LDHA (Lactate Dehydrogenase A) forward 
(5-CTGTTCCACTTAAGGCCCCTC-3), LDHA reverse 
(5-CCAGCCTTTCCCCCATTAGG-3), CAIX (Carbonic 
Anhydrase 9) forward (5-TACAGCTGAACTTCCGAG-
CG-3), CAIX reverse (5-CTAGGCTCCAGTCTCGGC-
TA-3), HPRT1 (Hypoxanthine-Guanine Phosphoribos-
yltransferase 1) forward (5-TGGCGTCGTGATTAGT-
GATG-3), HPRT1 reverse (5-TATCCAACACTTCGT-
GGGGT-3). All primers were manufactured by Sig-
ma-Aldrich. The PCR conditions for all of the analyzed 
genes were as following: denaturing at 95°C for 5 min-
utes, followed by 30 cycles of 30 seconds at 95°C, 30 
seconds at 58°C and 30 seconds at 72°C. The reaction 
was completed for 10 minutes at 72°C.
Scheme 1. The regulation of HIF-1 alpha level/stability. 
Under normoxic conditions, HIF-1 alpha is hydroxylated by spe-
cific prolyl hydroxylases (PHDs) in a reaction that requires O2, al-
lowing HIF-1 alpha binding with von Hippel-Lindau (VHL) protein 
to enable its ubiquitination and subsequent degradation by the 
proteasome machinery. Under hypoxic conditions, PHD is inactive 
and hydroxylation following subsequent polyubiquitination can-
not take place. Moreover, HIF-1 alpha stabilization/action is further 
enhanced by interactions with HSP90 which protects HIF-1 alpha 
subunit against VHL-independent proteasomal degradation. HIF-
1 alpha translocates to the nucleus and heterodimerizes with the 
HIF-1 beta subunit to regulate gene expression.
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Western Blot. Multiple myeloma cells were lysed di-
rectly in the sample buffer and harvested protein was 
separated by SDS/10% PAGE, and blotted. Prima-
ry rabbit anti-HIF-1 antibody (#3716, Cell Signalling) 
was detected by anti-rabbit IgG, HRP-linked Anti-
body (#7074, Cell Signalling), followed by visualization 
using ECL™ Western Blotting Detection Reagents (GE, 
Healthcare). Primary mouse monoclonal anti-β-actin an-
tibody (Clone AC-15, Sigma Aldrich) was detected by 
anti-mouse IgG, HRP-linked Antibody (#7076, Cell Sig-
nalling), followed by visualization using ECL Western 
Blotting Detection Reagents (GE, Healthcare). Digital 
images were taken with Bio-Rad ChemiDoc™ XRS+ 
System (Bio-Rad).
MTT (Methyl-Thiazolyl-Tertazolium) assay ad-
justed for cells cultured in suspension. The MTT 
assay was used as a survival assay and cytotoxicity as-
say for doxorubicin and bortezomib. Briefly, for sur-
vival assay, the myeloma cells (2 × 104 cells/well) were 
seeded into 96-well plates in 200 µl of RPMI1640 cul-
ture medium without phenol red (supplemented with 
100 units/ml penicillin and 100 µg/ml streptomycin) 
and cultured for 5 days with varying concentrations 
of FBS (0.5%, 1%, 2.5% and 5%). For cytotoxicity as-
say, the myeloma cells (4 × 104 cells/well) were seeded 
into 96-well plates and cultured with varying concen-
trations of doxorubicin and bortezomib in 200 µl of 
RPMI1640 culture medium without phenol red (sup-
plemented with 100 units/ml penicillin and 100 µg/
ml streptomycin and 5% FBS) for 48h. For 17-AAG 
cytotoxicity assessment, the myeloma cells (3 × 104 
cells/well) were seeded into 96-well plates and cul-
tured with varying concentrations of 17-AAG in 200 
µl of RPMI1640 culture medium without phenol red 
(supplemented with antibiotics and 5% FBS) for 24 h. 
Next, the cells were subjected to severe hypoxia for 
additional 72 h. In order to detect the living cells, af-
ter the incubation period, 10 μl of the dye (3, [4,5-di-
methylthiazol-2-yl-] diphenyltetrazolium bromide, 5 
mg/ml) (Sigma Aldrich) was added to each well and 
the plate was left at 37°C for 3 h. After that incuba-
tion period, the cells were lysed by adding 100 μl of 
the lysis buffer (10% SDS in 0.01 M HCl) and left 
for another 24 h at 37°C to complete the lysis. The 
viable cells were determined by measuring the opti-
cal density at 570 nm, using Synergy_HT plate reader 
(Biotek Instruments, USA).
RESULTS
Response of the malignant plasma cells to severe 
hypoxia
Initially, to validate our experimental setup, we deter-
mined the influence of severe hypoxia on malignant plas-
ma cells. Our Western blot analysis revealed the expected 
response to low oxygen environment, confirmed by sta-
bilization of the HIF-1 alpha subunit (Fig. 1, upper pan-
el). The characteristic 120 kDa alfa subunit band was de-
tected only in cells subjected to severe hypoxia, whereas 
in normoxic cells only the band of 100 kDa was visible 
on the exposed membrane, which most probably match-
es the degradation or cleavage product of HIF-1 alpha. 
To analyze the response at the mRNA level, we checked 
expression of genes (SLC2A1, PFKFB4, LDHA, CAIX) 
previously confirmed in the literature as the HIF-1 target 
genes (Harris, 2002; Minchenko et al., 2004), whose up-
regulation in low oxygen environment was published to 
occur in malignant plasma cells (Kocemba et al., 2013). 
In the L363 cell line, we confirmed the hypoxic induc-
tion of all analyzed genes by using the semi-quantitative 
RT-PCR, whereas in the RPMI 8226 cell line, the clear 
hypoxic induction was visible only in the case of CAIX 
and PFKFB4. Contrary to the L363 cell line, initial ex-
pression of LDHA and SLC2A1 in the RPMI 8226 cells 
was already high under normoxic conditions and was not 
further induced in severe hypoxia (Fig. 1 lower panel).
Survival of the malignant plasma cells under severe 
hypoxic conditions in the presence and absence of the 
HIF-1 inhibitor
In our study, we focused on 17-AAG, the HSP90 in-
hibitor, with confirmed anti-MM cytotoxicity (Mitsiades 
et al., 2006; Jurczyszyn et al., 2014). Although 17-AAG 
has been already reported as a compound inhibiting the 
HIF-1 pathway (Isaacs et al., 2002; Mitsiades et al., 2006), 
thus far there has been lack of data showing the hypoxia 
specific effect of 17-AAG on survival of malignant plas-
ma cells in a low oxygen environment. To investigate the 
hypoxia specific effect of 17-AAG on malignant plasma 
cells, we analysed the viability of cells cultured for 72 h 
under hypoxic and normoxic conditions in the presence 
and absence of this inhibitor, at the concentration range 
of 0.015–0.25 μM (Fig. 2A). Upon indicated time points, 
the number of living cells was assessed by the MTT 
assay adjusted for cells cultured in suspension. Inter-
estingly, for both cell lines we found concentrations of 
17-AAG that influenced the cells cultured under severe 
hypoxia more significantly than those cultured under 
normoxic conditions (Fig. 2A). In order to determine if 
17-AAG can influence the HIF-1 pathway in malignant 
plasma cells, we compared induction of the HIF-1 target 
genes in the cells cultured for 24 h under severe hypoxic 
conditions in the presence and absence of 17-AAG. As 
shown in Fig. 2B, 17-AAG significantly attenuated the 
Figure 1. Upper panel; HIF-1 alpha accumulation in L363 and 
RPMI 8226 MM cell lines. 
L363 and RPMI 8226 in response to hypoxia. MM cell lines were 
cultured under normoxic (-) or severe hypoxic (+) conditions 
for 24h. HIF-1 alpha was detected using Western blot. β-actin is 
shown as an internal control for equal protein loading. 
Lower panel; Induction of hypoxia target genes in MM cell lines. 
The expression of HIF-1 target genes was determined by RT-PCR 
following 24h exposure to normoxic (-) or severe hypoxic (+) con-
ditions. HPRT1 is shown as an internal control for equal amount 
of cDNA.
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severe hypoxia-induced expression of HIF-1 target genes 
in both cell lines. Thus, based on the data obtained we 
conclude that survival of malignant plasma cells under 
severe hypoxic conditions is influenced by inhibition of 
HSP90, which has been shown to affect the HIF-1 path-
way in MM.
Selection of the malignant plasma cells in cycling 
anoxia with and without the HIF-1 inhibitor
To investigate the influence of cyclic severe hypoxia 
on malignant plasma cells, we carried cell culture un-
der the severe hypoxia/re-oxygenation cycles. The goal 
of this experiment was to select the population able to 
survive under the severe hypoxic conditions. Of note, 
we observed that cycling severe hypoxia had a cell line 
specific influence on malignant plasma cells. Under the 
control conditions, in the absence of 17-AAG, when the 
short severe hypoxia re-oxygenation time points were 
applied, the cells continue to divide (Fig. 2C). Neverthe-
less, upon the last selection point the number of cells 
significantly declined in both cell lines. Moreover, the 
growth of cells cultured with 17-AAG (0.08 µM) was on 
the decline even during initial severe hypoxia re-oxygen-
ation time points. Particularly, in the case of the RPMI 
8226 cell line we initially observed growth inhibition 
only, whilst in the case of L363 an immediate drop in 
cell number was apparent (Fig. 2C). Of note, upon the 
last selection point in both cell lines in the presence of 
17-AAG (0.08 µM) only single living cells were detect-
ed, confirming much stronger selection pressure under 
HIF-1 inhibitory conditions. Since it is highly possible 
that hypoxic pressure can select for a particular subclone 
and/or cancer stem cells of a particular subclone, the re-
maining cells were further expanded and the newly se-
lected cell lines were subjected to a functional analysis.
Figure 2. (A) Anti-MM activity of 17-allylamino-17-demethoxygeldanamycin (17-AAG) under chronic severe hypoxic conditions.
MM RPMI 8226 and L363 cell lines (3 × 104cells/well) were cultured in normoxia and continuous severe hypoxia in the presence or ab-
sence of 17-AAG (0.015–0.25 μM). After 72h, the number of living cells was determined by MTT assay. The absorbance of cells under 
control conditions (without 17-AAG) was normalized to 1 and subsequently all results were normalized to the control values (untreat-
ed cells). The mean ± S.D. of a representative experiment performed in triplicate is shown. Student’s t-test was used for statistical data 
comparison between normoxic and severe hypoxic conditions. *indicates p value < 0.05, **indicates p value < 0.01, ***indicates p value 
< 0.001, by the Student’s t-test.
(B) Hsp90 inhibition targets HIF-1 signaling in MM.
The expression of HIF-1 target gene, SLC2A1, PFKFB4, LDHA, CAIX, and HPRT1 as the housekeeping control, was determined by RT-PCR 
following 24 h exposure to normoxia (–), severe hypoxia (+) and severe hypoxia in the presence of 17-AAG (1.25 µM).
(C) Anti-MM activity of 17-allylamino-17-demethoxygeldanamycin (17-AAG) under cyclic severe hypoxic conditions. 
MM L363 and RPMI 8226 cell lines were cultured in cycling severe hypoxia in the presence and absence of 17-AAG (0.08 µM). Upon in-
dicated time points (start, sel1, sel2, sel3, sel4) the number of living cells was determined by MTT assay. The absorbance of cells at day 0 
was normalized to 1 and subsequently all of the results were normalized to day 0. Start – day 0, Sel1 – selection point 1; 24 h normoxia, 
24 h severe hypoxia, Sel2 – selection point 2; 24 h normoxia, 24 h severe hypoxia, 2 h re-oxygenation, 16 h severe hypoxia, Sel3 – se-
lection point 3; 24 h normoxia, 24 h severe hypoxia, 2 h re-oxygenation, 16 h severe hypoxia, 8 h re-oxygenation, 24 h severe hypoxia, 
Sel4 – selection point 4; 24 h normoxia, 24 h severe hypoxia, 2 h re-oxygenation, 16 h severe hypoxia, 8 h re-oxygenation, 24 h severe 
hypoxia, 2 h re-oxygenation, 72 h severe hypoxia.
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Functional analysis of the malignant plasma cells 
selected under severe hypoxia/re-oxygenation culture 
conditions with and without HIF-1 inhibition
Functional analysis of cells selected under severe 
hypoxic conditions comprised studying response to 
different serum concentrations and the response to 
chemotherapeutics commonly used in the treatment of 
MM. First, we compared the influence of decreasing 
serum concentrations on L363 and RPMI 8226 cells 
selected under severe hypoxic conditions in the pres-
ence and absence of the HSP90 inhibitor. As shown in 
Figure 3A, the selected cells of RPMI 8226 responded 
differently to the decreasing serum content in the cul-
ture medium. Interestingly, however, our survival as-
say revealed that the RPMI 8226 cells selected under 
severe hypoxia with and without 17-AAG were more 
dependent on growth factors in comparison to the pa-
rental cells (Fig. 3A). Contrary, in the L363 cells we 
did not observe any relevant differences under vary-
ing growth conditions (Fig. 3A) among the analyzed 
parental and selected cell lines. Next, we analyzed the 
response of malignant plasma cells selected under dif-
ferent conditions, to the chemotherapeutics commonly 
used in advanced MM (Palumbo et al., 2008). We ana-
lyzed the response to bortezomib (6.25 nM to 25 nM) 
and doxorubicine (18.75 nM to 150 nM). As shown 
in Fig. 3B, in the L363 cells selected under hypoxic 
conditions with and without 17-AAG, repeatedly dem-
onstrated lower sensitivity to certain concentrations of 
doxorubicin (75 nM, 150 nM) and bortezomib (12.5 
Figure 3. (A) Survival assay of malignant plasma cells selected under severe hypoxic conditions in the presence and absence of 
17-allylamino-17-demethoxygeldanamycin (17-AAG).
Multiple myeloma cells (2 × 104 cells/well) were seeded into 96-well plates and cultured with varying concentrations (0.5%, 1%, 2.5%, 5%) 
of serum for 5 days. The number of living cells was determined by MTT assay. The absorbance of cells under control conditions (5% 
serum) was normalized to 1 and subsequently the results obtained with different serum concentrations were normalized to the control 
conditions (5% serum FBS). The response to indicated serum concentration was performed for parental cell lines (L363, RPMI 8226), cells 
selected under severe hypoxic conditions (L363 Hyp, RPMI 8226 Hyp) and the cells selected under severe hypoxic conditions in the pres-
ence of 0.08 µM 17-AAG (L363 Hyp17-AAG, RPMI 8226 Hyp 17-AAG). The mean ± S.D. of a representative experiment performed in tripli-
cate is shown. Student’s t-test was used for statistical data comparison. *indicates p value < 0.05, **indicates p value < 0.01, ***indicates p 
value < 0.001, by the Student’s t-test.
(B) Effect of doxorubicin and bortezomib on malignant plasma cells selected under severe hypoxic conditions in the presence and 
absence of 17-allylamino-17-demethoxygeldanamycin (17-AAG).
Multiple myeloma cells (4 × 104 cells/well) were seeded into 96-well plates and cultured with varying concentrations of doxorubicin 
(18.75–150 nM) and bortezomib (6.25–25 nM) for 48 h. The number of living cells was determined by MTT assay. The absorbance of cells 
under control conditions was normalized to 1 and subsequently all the results were normalized to the control conditions (without chem-
otherapeutics). The response to chemotherapeutics was carried out for parental cell lines (L363, RPMI 8226), cells selected under severe 
hypoxic conditions (L363 Hypoxia, RPMI 8226 Hypoxia) and the cells selected under severe hypoxic conditions in the presence of 17-AAG 
(L363 Hypoxia 17-AAG, RPMI 8226 Hypoxia 17-AAG) (0.08 µM). The mean ± S.D. of a representative experiment performed in triplicate is 
shown. Student’s t-test was used for statistical data comparison. *indicates p value < 0.05, **indicates p value < 0.01, ***indicates p value 
< 0.001, by the Student’s t-test.
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nM), whereas in the RPMI 8226 cell line we did not 
observe any reproducible changes between the paren-
tal cell line and the cells selected under severe hypox-
ic conditions in response to the analyzed chemothera-
peutics (Fig. 3B).
DISCUSSION
Previous research analysing the behaviour of cells in 
low oxygen environment pointed to HIF-1 as a crucial 
transcription factor mediating cellular response to hypoxia 
(Semenza, 2003; 2007). Study by Semenza et al. revealed 
that the HIF-1 transcription factor is responsible for ad-
aptation to low oxygen environment by increasing the glu-
cose transport and its breakdown, allowing the adequate 
ATP production despite the reduced efficiency of anaer-
obic metabolism, among others (Semenza, 2002; 2003). 
We have previously demonstrated that hypoxia enhances 
the angiogenic potential of malignant plasma cells contrib-
uting directly to MM-induced angiogenesis (Kocemba et 
al., 2013), the process crucial for expansion of malignant 
plasma cells in the bone marrow (Giulani et al., 2011). Al-
though anti-angiogenic therapy was enthusiastically admit-
ted in the cancer field, the angiogenesis inhibitors fail to 
produce sustained clinical response in many patients and 
resistance to anti-angiogenic agents frequently develops 
(Vasudev & Reynolds, 2014). The disappointing perfor-
mance of the anti-angiogenic agents may very well be the 
consequence of hypoxia and nutrient limitations occurring 
after devascularisation. These alterations force the acquisi-
tion of mutations in cells which may lead to selection of 
more aggressive clones able to survive beyond the original 
limitations (Ebos et al., 2009; Loges et al., 2009; Paez-Ri-
bes et al., 2009; Mcintyre & Harris, 2015). In order to find 
a potential solution, researchers have tested therapeutic 
approaches targeting the hypoxic tumour compartment to 
prevent the survival and selection of cells in low oxygen 
micro-environment (Xia et al., 2012). In this study we re-
vealed that 17-allylamino-17-demethoxygeldanamycin, a 
heat shock protein 90 inhibitor, selectively targets the se-
vere hypoxic malignant plasma cells, in the range of con-
centrations tested. Of note, to the best of our knowledge, 
this is the first report showing that 17-AAG can block 
induction of HIF-1 target genes in malignant plasma cells 
under hypoxic conditions. Although the influence of 17-
AAG on the HIF-1 pathway was already reported in ma-
lignant plasma cells by Mitsiades and coworkers (Mitsiades 
et al., 2006), these authors revealed the impact of 17-AAG 
only at the basal, normoxic HIF-1 transcriptional activity.
Although 17-AAG seems to be toxic for malignant 
plasma cells cultured in low oxygen environment, we 
cannot exclude that by acting on the cells in the hy-
poxic/anoxic niches the selection pressure is further 
enhanced, namely the cells which are able to survive 
under severe hypoxic conditions without active HIF-1 
transcription factor are subjected to double stress – the 
lack of oxygen and incapability for metabolic reprogram-
ming initiated by the HIF-1 transcription factor. More-
over, HIF-1 attenuation may contribute to an increase in 
the oxidative stress (Zhao et al., 2014), leading to high-
er rates of oxidative damage and the acquisition of new 
mutations in the cells. Thus, there is a possibility that 
HIF-1 inhibitors may select for more aggressive clones, 
with additional mutations in genes important for tumour 
metabolism. On the other hand, it has been reported 
that mouse lymphoma and Acute Myeloid Leukemia 
(AML) cancer stem cells (CSCs) were selectively sensitive 
to low concentration of 17-AAG (Newman et al., 2012). 
That effect was the consequence of the loss of HIF-1 
function, which is crucial for the maintenance of both, 
mouse lymphoma and AML CSCs. To further validate 
the influence of 17-AAG on MM stem cells (MMSC) 
would be definitely of high importance, nevertheless, the 
most significant problem so far is to isolate the popula-
tion of MMSC in order to study and definitely describe 
their unique biology (Kellner et al., 2013). As a conse-
quence, the interest of current studies in the field of MM 
focuses on clonal heterogeneity and related differential 
response to targeted therapies (Keats et al., 2012; Bolli 
et al., 2014; Lohr et al., 2014; Melchor et al., 2014). Al-
though the next generation sequencing method has been 
already applied in MM patients to track the alterations 
in clonal structure induced by particular treatment (Bolli 
et al., 2014), according to our knowledge, no study so 
far has implemented this type of analysis in a model of 
hypoxia and/or anoxia. For our analysis we chose two 
MM cell lines in which analysis of karyotypes’ structure 
confirmed clonal heterogeneity. In L363 cell line two 
main structural variants of karyotype were determined, 
whereas in RPMI 8226 cells a significant karyotypic 
heterogeneity was reported. The main structural variant 
of karyotype in the RPMI 8226 cells was detected only 
in 42% of cells, whereas the remaining cells contained 
non-clonal chromosome rearrangements (Turilova et al., 
2012). Functional studies of hypoxia/anoxia selected 
cells, which we propose in this paper, may serve as an 
initial step in studying the changes in malignant plasma 
cells selected in low oxygen environment, and depend-
ing on the results, they may give the basis for more ad-
vanced investigation. In our experiment, the number of 
cells which survived the anoxia/re-oxygenation culture 
conditions in the presence of 17-AAG was much lower 
in comparison to anoxia/re-oxygenation alone, showing 
the much stronger selection pressure in the presence of 
the compound inhibiting HIF-1 pathway. Interestingly, 
our data revealed that RPMI 8226 cells selected in cy-
clic severe hypoxia are more dependent on growth fac-
tors in comparison to the parental line. Of note, higher 
growth factor sensitivity was observed in both RPMI 
8226 selected cell lines, obtained either by severe hy-
poxia/re-oxygenation selection alone or severe hypoxia/
re-oxygenation selection combined with 17-AAG appli-
cation, which suggests that the altered response to se-
rum-derived growth factors was induced exclusively by 
the severe hypoxic environment. According to literature, 
RPMI 8226 cells show lower cytokine sensitivity in com-
parison to L363 cells in an experimental culture, and our 
data obtained for parental cell lines seems to be consen-
tient with this observation (Zlei et al., 2007). In contrast, 
the high growth factor sensitivity observed exclusively 
in RPMI 8226 selected cells may reflect selection of a 
particular subclone, highly sensitive to external growth 
factors.
As for the alterations in the L363 cells selected in cy-
clic severe hypoxia, we demonstrated inferior sensitivity 
to doxorubicin and bortezomib for both L363 selected 
cell lines, obtained either by severe hypoxia/re-oxygen-
ation selection alone or severe hypoxia/re-oxygenation 
selection combined with 17-AAG application. Of note, 
the decreased sensitivity to bortezomib and doxorubicin 
may very well be the consequence of the acquired alter-
ations in selected cells which interfere with the mech-
anism of actions for these chemotherapeutics. Briefly, 
bortezomib, formerly known as Velcade, PS-341, is a 
boronic acid dipeptide, which reversibly and highly se-
lectively inhibits the catalytic site of the 26S proteasome, 
an enzyme complex that plays a key role in degradation 
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of ubiquitylated, abnormal or misfolded proteins (Ad-
ams et al., 2004). The anti-Multiple Myeloma action of 
bortezomib is related to inhibition of NF-κB (Nucle-
ar Factor kappa B) signalling (Hideshima et al., 2001), 
through prevention of IκBα degradation and triggering 
of the unfolded protein response (UPR) (Obeng et al., 
2006). Interestingly, unfolded protein response is also 
triggered by severe hypoxic conditions with subsequent 
transcriptional expression increase of ATF4 (Activat-
ing transcription factor 4) transcription factor activating 
genes that promote restoration of normal ER (Endo-
plasmic Reticulum) function and survival under hypox-
ia (Rzymski et al., 2010). Moreover, ATF4 also plays a 
crucial role in resistance to bortezomib by the induction 
of pro-survival pathways, such as autophagy, that can 
relieve the protein overload in bortezomib treated cells 
(Rzymski et al., 2010). Thus, it can be hypothesize that 
the cells which survived the severe hypoxic conditions 
have a higher basal or UPR induced expression level of 
ATF4, which eventually may result in lower sensitivity to 
proteasome inhibitors. As for doxorubicin, there are two 
proposed mechanisms of its ant-cancer activities; interca-
lation into DNA and disruption of topoisomerase-II-me-
diated DNA repair and generation of free radicals lead-
ing to oxidative stress damaging all cellular components 
(Gewirtz et al., 1999). The response to reactive oxygen 
species (ROS) may be modulated by an enzyme capable 
of deactivating the free radicals, such as glutathione per-
oxidase, catalase, and superoxide dismutase (Liou et al., 
2010). As excessive ROS production is well documented 
during a severe hypoxia/reoxygenation process (Granger 
et al., 2015), therefore it is possible that the selected cells 
have higher expression level or activity of an enzyme re-
sponsible for free radicals’ deactivation and as a conse-
quence they may show lower sensitivity to doxorubicin.
Although it has been known that HIF-1 can directly 
induce drug resistance by several independent mecha-
nisms (Rohwer & Cramer, 2011), in our study we have 
shown that just severe hypoxic selection itself can trig-
ger the direct chemotherapeutics’ resistance in malignant 
plasma cells which may results from the acquisition of 
molecular alterations in the selected cells which interfere 
with the bortezomib and doxorubicin mechanisms of 
action. Importantly, the fact that we again observed the 
same phenomenon in the cells selected with and without 
17-AAG, derived from the same parental cell line, sug-
gests that the low oxygen environment served as a major 
selection factor in our experimental setup.
 In fact, the observed functional changes can very well 
be the consequence of pre-existing subclonal structure 
of the analyzed cell lines and severe hypoxia – induced 
selection of the clones with distinct genetic profile. In-
deed, by the use of a single cell transcriptomics analy-
sis a study by Mitra and coworkers (Mitra et al., 2014) 
identified a subclonal structure within Human Myeloma 
Cell Lines (HMCLs) subjected to bortezomib treatment. 
Moreover, significant genetic diversity at subclonal lev-
els has been proved as a driving force in the evolution 
of MM (Keats et al., 2012; Lohr et al., 2014; Melchor et 
al., 2014). Nevertheless, in relation to severe hypoxia, 
more advanced studies would be required to answer the 
intriguing question if severe hypoxia-induced selection 
process is in any way influenced by subclonal structure 
of the analyzed cell lines. This type of research seems 
to be highly rational since hypoxia is one of the strong-
est micro-environmental selection factors (Graeber et 
al., 1996), whereas most MM cases demonstrate a com-
plex subclonal structure (Bolli et al., 2014). Alternatively, 
in addition to hypoxia induced subclonal selection, the 
observed changes can be the consequence of severe hy-
poxia – triggered long term epigenetic alterations in the 
selected cells. Interestingly, recently published studies 
confirmed that low oxygen environment induces chang-
es in the histone modifications and DNA methylation 
(Lu et al., 2011; Tsai et al., 2014; Thienpont et al., 2016) 
leading in consequence to a hypoxia-adapted phenotype 
which can be maintained in the absence of HIF-1 (Wat-
son et al., 2010; Thienpont et al., 2016). Thus, the func-
tional changes observed in severe hypoxia selected MM 
cells can be in fact the consequence of both, selection 
of a particular subclone with additional severe hypoxia-
triggered new epigenetic pattern.
In conclusion, our data show that the selection in low 
oxygen environment, as expected, induces functional 
changes in malignant plasma cells. Of note, the enhance-
ment of selection pressure by the addition of HIF-1 
inhibiting compound did not further augment the ag-
gressiveness of selected cells, pointing to 17-AAG as a 
potential anti-MM agent with severe hypoxia specific cy-
totoxicity. Similarities observed in cells selected by severe 
hypoxic condition alone, as well as by severe hypoxia 
combined with HIF-1 inhibiting compound, seem to in-
dicate that the lack of oxygen itself is the main/pivotal 
factor driving the selection process. Definitely, it would 
be very interesting to apply the advanced techniques as 
e.g. massive parallel sequencing, to answer the question 
if clonal evolution may contribute in any way to hypoxia 
resistance and if treatment with HIF-1 pathway inhibi-
tors may further influence this process.
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